2A91 McCue, Peter A. - Thomas Jefferson University - Thomas Jefferson University
pxm129

Peter A. McCue, MD

Contact Dr. McCue

132 S. 10th Street
Main Building, Suite 285
Philadelphia, PA 19107

(215) 955-5588

Most Recent Peer-reviewed Publications

  1. Comprehensive Immunohistochemical Study of Programmed Cell Death Ligand 1 (PD-L1): Analysis in 5536 Cases Revealed Consistent Expression in Trophoblastic Tumors
  2. VPAC1 targeted 64Cu-TP3805 positron emission tomography imaging of prostate cancer: Preliminary evaluation in man
  3. Structure-based screen identifies a potent small molecule inhibitor of Stat5a/b with therapeutic potential for prostate cancer and chronic myeloid leukemia
  4. Paracrine effect of NRG1 and HGF drives resistance to MEK inhibitors in metastatic uveal melanoma
  5. The endogenous cell-fate factor dachshund restrains prostate epithelial cell migration via repression of cytokine secretion via a CXCL signaling module
  6. Sox10 - A marker for not only schwannian and melanocytic neoplasms but also myoepithelial cell tumors of soft tissue: A systematic analysis of 5134 tumors
  7. Jak2-Stat5a/b Signaling Induces Epithelial-to-Mesenchymal Transition and Stem-Like Cell Properties in Prostate Cancer
  8. Genomic prostate cancer classifier predicts biochemical failure and metastases in patients after postoperative radiation therapy
  9. Expression of insulin-like growth factor-1 receptor in metastatic uveal melanoma and implications for potential autocrine and paracrine tumor cell growth
  10. A systematic immunohistochemical study of 3215 cases
  11. Predictors of positive surgical margins after radical prostatectomy at a single institution: Preoperative and pathologic factors, and the impact of surgeon variability and technique on incidence and location
  12. Mapping of succinate dehydrogenase losses in 2258 epithelial neoplasms
  13. GATA3: A multispecific but potentially useful marker in surgical pathology: A systematic analysis of 2500 epithelial and nonepithelial tumors
  14. Targeting cell cycle and hormone receptor pathways in cancer
  15. Pharmacologic inhibition of Jak2-Stat5 signaling by Jak2 inhibitor AZD1480 potently suppresses growth of both primary and castrate-resistant prostate cancer
  16. Sarcoidosis mimicking metastatic bone disease in head and neck cancer
  17. Molecular diagnosis of prostate cancer: Are we up to age?
  18. STAT5A/B gene locus undergoes amplification during human prostate cancer progression
  19. Aberrant BAF57 signaling facilitates prometastatic phenotypes
  20. Novel oncogene-induced metastatic prostate cancer cell lines define human prostate cancer progression signatures
0